REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: ...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership ...

Alvotech (NASDAQ:ALVO) and partner Teva Pharmaceuticals (NYSE:TEVA) announced Friday the U.S. Food and Drug Administration (FDA) approval for their arthritis injection, Simlandi (adalimumab-ryvk).

Humira (adalimumab) treats certain types of arthritis and inflammatory diseases. This prescription drug is a liquid for injection under your skin. Humira may not be safe to receive while pregnant but ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...

FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

Orencia (abatacept) and Humira (adalimumab) are prescription drugs used to treat inflammatory arthritis. They have other uses as well. Both drugs can be given as an injection under the skin. This ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

WASHINGTON, Aug 24 (Reuters) - Abbott Laboratories Inc may need to conduct additional trials of Humira to prove the blockbuster drug helps patients with ulcerative colitis, U.S. drug reviewers said on ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...

For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (ABBV +0.59%) blockbuster immunology drug facing competition. After all, at its peak, Humira brought ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...